Novel Genetic and Phenotypic Expansion in GOSR2-Related Progressive Myoclonus Epilepsy

Genes (Basel). 2023 Sep 25;14(10):1860. doi: 10.3390/genes14101860.

Abstract

Biallelic variants in the Golgi SNAP receptor complex member 2 gene (GOSR2) have been reported in progressive myoclonus epilepsy with neurodegeneration. Typical clinical features include ataxia and areflexia during early childhood, followed by seizures, scoliosis, dysarthria, and myoclonus. Here, we report two novel patients from unrelated families with a GOSR2-related disorder and novel genetic and clinical findings. The first patient, a male compound heterozygous for the GOSR2 splice site variant c.336+1G>A and the novel c.364G>A,p.Glu122Lys missense variant showed global developmental delay and seizures at the age of 2 years, followed by myoclonus at the age of 8 years with partial response to clonazepam. The second patient, a female homozygous for the GOSR2 founder variant p.Gly144Trp, showed only mild fine motor developmental delay and generalized tonic-clonic seizures triggered by infections during adolescence, with seizure remission on levetiracetam. The associated movement disorder progressed atypically slowly during adolescence compared to its usual speed, from initial intention tremor and myoclonus to ataxia, hyporeflexia, dysmetria, and dystonia. These findings expand the genotype-phenotype spectrum of GOSR2-related disorders and suggest that GOSR2 should be included in the consideration of monogenetic causes of dystonia, global developmental delay, and seizures.

Keywords: GOSR2; North Sea progressive myoclonus epilepsy; clonazepam; dystonia; vesicular trafficking.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Ataxia / genetics
  • Child
  • Child, Preschool
  • Dystonia*
  • Dystonic Disorders*
  • Female
  • Humans
  • Male
  • Mutation
  • Myoclonic Epilepsies, Progressive* / genetics
  • Myoclonus*
  • Qb-SNARE Proteins / genetics
  • Seizures

Substances

  • GOSR2 protein, human
  • Qb-SNARE Proteins

Grants and funding

Lea Hentrich was supported by the Koeln Fortune Program/Faculty of Medicine, University of Cologne (259/2022). Heinz Jungbluth was supported by Action Medical Research, United Kingdom, the GOSH Charity/Sparks, and European Commission H2020-MSCA-ITN-2017. Hormos Salimi Dafsari was supported by the Koeln Fortune Program/Faculty of Medicine, University of Cologne (371/2021 and 243/2022), as well as the Cologne Clinician Scientist Program/Medical Faculty/University of Cologne and German Research Foundation (CCSP, DFG project no. 413543196). We acknowledge support for the Article Processing Charge from the DFG (German Research Foundation, 491454339).